

Washington State Pharmacy and Therapeutics Committee & Drug Utilization Review Board
Meeting by Zoom Webinar
Wednesday, December 14, 2022 9 a.m. to 3:20 p.m.

Agenda		
Time	Topic	Presenter
9 a.m.	Welcome & Introductions Vote on vice chair for 2023 Pharmacy & Therapeutics (P&T) Committee Convenes (Reviews drug classes for the WA PDL)	Jordan Storhaug, Committee Chair
9:05 a.m.	Asthma/COPD- report <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Shannon Robalino, DERP
10:20 a.m.	Pharmacy & Therapeutics Committee Adjourns Break (10 min)	Jordan Storhaug, Committee Chair All
10:30 a.m.	Drug Utilization Review (DUR) Board Convenes (Reviews drug classes for the Apple Health PDL)	Jordan Storhaug, Committee Chair
10:30 a.m.	Analgesics <ul style="list-style-type: none"> • Opioid Agonists - Long Acting <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
10:35 a.m.	Antiemetics / Antivertigo Agents <ul style="list-style-type: none"> • 5-HT3 Receptor Antagonists • Substance P/Neurokinin 1 (NK1) Receptor Antagonists • Substance P/Neurokinin 1 Receptor Antagonist Combinations <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
10:40 a.m.	Antihypertensives <ul style="list-style-type: none"> • Direct Renin Inhibitor Combinations • Direct Renin Inhibitors • Nephilysin Inhib (ARNI)-Angiotensin II Recept Antag Combinations <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
10:50 a.m.	Antivirals <ul style="list-style-type: none"> • Hepatitis C Agents <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
11:05 a.m.	Anticonvulsants <ul style="list-style-type: none"> • AMPA Glutamate Receptor Antagonists • Benzodiazepines - Rescue Agents 	

** Stakeholders will be allowed 3 minutes for comments.*

Committee discussion and motions will follow stakeholder comments.

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Leta Evaskus at 206-521-2029.

	<ul style="list-style-type: none"> • Misc • Succinimides <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	
12:05 p.m.	Lunch (30 min)	All
12:35 p.m.	Endocrine and Metabolic Agents <ul style="list-style-type: none"> • Androgens - Testosterone <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
12:45 p.m.	Migraine Agents <ul style="list-style-type: none"> • Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists • Selective Serotonin Agonists 5-HT(1) <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
1 p.m.	Pulmonary Hypertension Agents <ul style="list-style-type: none"> • Endothelin Receptor Antagonists • Prostacyclin Receptor Agonists • Prostaglandin Vasodilators • SGC Stimulator • Phosphodiesterase Inhibitors (PDEI) <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
1:15 p.m.	Antidementia Agents <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Umang Patel, Magellan
1:25 p.m.	Break (10 min)	All
1:35 p.m.	Atopic Dermatitis Agents <ul style="list-style-type: none"> • Immunosuppressive Agents - Topical • Monoclonal Antibodies • Phosphodiesterase 4 Inhibitors - Topical <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
1:55 p.m.	Cytokine and CAM Antagonists <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Umang Patel, Magellan
3:20 p.m.	Drug Utilization Review Board Adjourns	Jordan Storhaug, Committee Chair

For all Apple Health (Medicaid) questions:

1. Go to [HCA Support](#).
2. Click **Public**. You will need a SecureAccess Washington (SAW) account. ([View instructions for accessing SAW.](#))
3. Once you have logged into SAW, you will see the HCA Support portal.
4. Click **Make a Request**.
5. Click the **Apple Health Pharmacy** tile. This will take you to the online form.

** Stakeholders will be allowed 3 minutes for comments.*

Committee discussion and motions will follow stakeholder comments.

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Leta Evaskus at 206-521-2029

